These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22745543)

  • 1. pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy.
    Shin JY; Yang Y; Heo P; Lee JC; Kong B; Cho JY; Yoon K; Shin CS; Seo JH; Kim SG; Kweon DH
    Int J Nanomedicine; 2012; 7():2805-16. PubMed ID: 22745543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells.
    Zhang BB; Chen XJ; Fan XD; Zhu JJ; Wei YH; Zheng HS; Zheng HY; Wang BH; Piao JG; Li FZ
    Acta Pharmacol Sin; 2021 May; 42(5):832-842. PubMed ID: 33824461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma.
    Li X; Qin F; Yang L; Mo L; Li L; Hou L
    Int J Nanomedicine; 2014; 9():3971-85. PubMed ID: 25170267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer.
    Min SY; Byeon HJ; Lee C; Seo J; Lee ES; Shin BS; Choi HG; Lee KC; Youn YS
    Int J Pharm; 2015 Oct; 494(1):506-15. PubMed ID: 26315118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel-loaded pH responsive hydrogel based on self-assembled peptides for tumor targeting.
    Raza F; Zhu Y; Chen L; You X; Zhang J; Khan A; Khan MW; Hasnat M; Zafar H; Wu J; Ge L
    Biomater Sci; 2019 Apr; 7(5):2023-2036. PubMed ID: 30839983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrogen-Bonded Tannic Acid-Based Anticancer Nanoparticle for Enhancement of Oral Chemotherapy.
    Le Z; Chen Y; Han H; Tian H; Zhao P; Yang C; He Z; Liu L; Leong KW; Mao HQ; Liu Z; Chen Y
    ACS Appl Mater Interfaces; 2018 Dec; 10(49):42186-42197. PubMed ID: 30444601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-circulating self-assembled cholesteryl albumin nanoparticles enhance tumor accumulation of hydrophobic anticancer drug.
    Battogtokh G; Kang JH; Ko YT
    Eur J Pharm Biopharm; 2015 Oct; 96():96-105. PubMed ID: 26212785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing combination of artesunate with paclitaxel loaded into poly-d,l-lactic-co-glycolic acid nanoparticle for systemic delivery to exhibit synergic chemotherapeutic response.
    Tran BN; Nguyen HT; Kim JO; Yong CS; Nguyen CN
    Drug Dev Ind Pharm; 2017 Dec; 43(12):1952-1962. PubMed ID: 28724314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ethylene oxide)-block-polyphosphoester-graft-paclitaxel conjugates with acid-labile linkages as a pH-sensitive and functional nanoscopic platform for paclitaxel delivery.
    Zou J; Zhang F; Zhang S; Pollack SF; Elsabahy M; Fan J; Wooley KL
    Adv Healthc Mater; 2014 Mar; 3(3):441-8. PubMed ID: 23997013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction-Triggered Paclitaxel Release Nano-Hybrid System Based on Core-Crosslinked Polymer Dots with a pH-Responsive Shell-Cleavable Colorimetric Biosensor.
    Kim SG; Ryplida B; Phuong PTM; Won HJ; Lee G; Bhang SH; Park SY
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of paclitaxel-loaded poly (2-hydroxyethyl methacrylate)-g-poly (lactide)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine copolymer nanoparticle delivery system and evaluation of its anticancer activity.
    Ma X; Wang H; Jin S; Wu Y; Liang XJ
    Int J Nanomedicine; 2012; 7():1313-28. PubMed ID: 22419875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly(cystine-PCL) based pH/redox dual-responsive nanocarriers for enhanced tumor therapy.
    Zhang X; Kang Y; Liu GT; Li DD; Zhang JY; Gu ZP; Wu J
    Biomater Sci; 2019 Apr; 7(5):1962-1972. PubMed ID: 30810135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment.
    Yang D; Van S; Liu J; Wang J; Jiang X; Wang Y; Yu L
    Int J Nanomedicine; 2011; 6():2557-66. PubMed ID: 22072890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction/Oxidation-Responsive Hierarchical Nanoparticles with Self-Driven Degradability for Enhanced Tumor Penetration and Precise Chemotherapy.
    Yin S; Gao Y; Zhang Y; Xu J; Zhu J; Zhou F; Gu X; Wang G; Li J
    ACS Appl Mater Interfaces; 2020 Apr; 12(16):18273-18291. PubMed ID: 32223148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zein-Paclitaxel Prodrug Nanoparticles for Redox-Triggered Drug Delivery and Enhanced Therapeutic Efficiency.
    Hou H; Zhang D; Lin J; Zhang Y; Li C; Wang Z; Ren J; Yao M; Wong KH; Wang Y
    J Agric Food Chem; 2018 Nov; 66(44):11812-11822. PubMed ID: 30339011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoparticles Containing High Loads of Paclitaxel-Silicate Prodrugs: Formulation, Drug Release, and Anticancer Efficacy.
    Han J; Michel AR; Lee HS; Kalscheuer S; Wohl A; Hoye TR; McCormick AV; Panyam J; Macosko CW
    Mol Pharm; 2015 Dec; 12(12):4329-35. PubMed ID: 26505116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the pH Dependent Cytotoxicity of Paclitaxel Conjugated Gold Nanoparticles.
    Alhalili Z; Shapter J; Auliya NH; Sandersonb B
    Pharm Nanotechnol; 2017; 5(2):111-118. PubMed ID: 28440201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pH and glutathion-responsive hydrogel for localized delivery of paclitaxel.
    Pérez E; Fernández A; Olmo R; Teijón JM; Blanco MD
    Colloids Surf B Biointerfaces; 2014 Apr; 116():247-56. PubMed ID: 24491841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of polymeric pH-sensitive STEALTH® nanoparticles for tumor delivery of a lipophilic prodrug of paclitaxel.
    Lundberg BB
    Int J Pharm; 2011 Apr; 408(1-2):208-12. PubMed ID: 21296135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy.
    Li Y; Hou H; Zhang P; Zhang Z
    Drug Deliv; 2020 Dec; 27(1):1044-1053. PubMed ID: 32633576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.